In a retrospective study of 315 patients with relapsed/refractory multiple myeloma, retreatment with previously refractory ...

A team of researchers from the Translational Oncology Research Centre (TORC) of Vrije Universiteit Brussel (VUB), in ...

AbbVie and Simcere Zaiming have announced a partnership worth over $1bn to develop an investigational drug candidate for ...

The humanised trispecific antibody is undergoing Phase I trials in the US and China in subjects with relapsed or refractory ...

The team tackled a critical challenge in treating multiple myeloma-a blood cancer where malignant plasma cells accumulate in bone marrow, leading to debilitating bone lesions in 80% of patients.

Researchers sought to determine whether patients who are functional high-risk had a worse prognosis even without having traditional high-risk features.

EsoBiotec, which has successfully advanced its ESO-T01 in vivo CAR-T candidate into clinical trials. ESO-T01 is the first in vivo B-cell maturation antigen (BCMA) CAR-T candidate to reach the clinical ...

Analyst Edward White of H.C. Wainwright reiterated a Buy rating on Karyopharm Therapeutics (KPTI – Research Report), retaining the price target ...

GSK plans five new product approvals by 2025, highlights strong specialty growth, and acquires IDRx for $1 billion to expand its oncology portfolio.

Kate Middleton left a lasting impression on one of the cancer patients at the hospital where she was treated for her health ...

Leerink Partners analyst Thomas Smith has reiterated their bullish stance on RNAC stock, giving a Buy rating on January 13.Stay Ahead of the ...